Data CollectionNCT07911618
Data Collection For Patients With Sickle Cell Disease
An observational study of Data Collection and Sickle Cell Disease, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To create a database of clinical information, participant /disease characteristics, and treatment history collected from patients with Sickle Cell Disease. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Data Collection, Sickle Cell Disease
- What is being tested?
- data collection
- How many people
- 500 participants
- Where
- 1 siteUnited States
- Study dates
- 6 Apr 2027to 1 Jan 2037
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: UT MD Anderson Cancer Center
Who may be able to join
- Participants 18 years of age and older diagnosed with Sickle Cell Disease.
- Participants treated at UT Physicians Sickle Center Cancer Center
- Participants treated at UT MD Anderson Cancer Center
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
UT MD Anderson Cancer Center
Houston, Texas, 77030
Kebriaei,Partow Kebriaei, MD, 713-745-0663, pkebriae@mdanderson.org
Partow Kebriaei, MD
About this study
To create a database of clinical information, participant /disease characteristics, and treatment history collected from patients with Sickle Cell Disease.
Read the detailed description
Primary Objective To collect comprehensive data from patients who are being treated at UT Physicians and UT MDACC for sickle cell disease.
- Conditions
- Data Collection, Sickle Cell Disease
- Being tested
- data collection
- Medical subject headings
- Anemia, Sickle Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
data collectionOther
Data will be extracted from the electronic medical record system at UT Physicians and UT MDACC.
What is being measured
The primary outcome is the main question the study is designed to answer.
safety and adverse events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured: Through study completion; an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2026
- Study start6 Apr 2027 (estimated)
- Primary completion1 Jan 2035 (estimated)
- Study completion1 Jan 2037 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Data CollectionStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Partow Kebriaei, MD, Principal investigator, UT MD Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07911618
- Sponsor's protocol ID
- 2026-0951
- Other IDs
- NCI-2026-08130
- Status last verified
- Oct 2026
- First submitted
- 28 Oct 2026
- Last updated
- 3 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Data Collection For Patients With Sickle Cell Disease
- ClinicalTrials.gov ID
- NCT07911618
- Acronym / sponsor ID
- 2026-0951
- Conditions
- Data Collection, Sickle Cell Disease
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 6 Apr 2027 (estimated)
- Primary completion
- 1 Jan 2035 (estimated)
- Study completion
- 1 Jan 2037 (estimated)
- First posted
- 3 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To create a database of clinical information, participant /disease characteristics, and treatment history collected from patients with Sickle Cell Disease.
Detailed description
Primary Objective To collect comprehensive data from patients who are being treated at UT Physicians and UT MDACC for sickle cell disease.
Study design
- Observational model
- Cohort
- Time perspective
- Other
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- UT MD Anderson Cancer Center
Key inclusion criteria (3 listed)
- Participants 18 years of age and older diagnosed with Sickle Cell Disease.
- Participants treated at UT Physicians Sickle Center Cancer Center
- Participants treated at UT MD Anderson Cancer Center
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| data collectionData will be extracted from the electronic medical record system at UT Physicians and UT MDACC. | Other | – |
Primary outcome
safety and adverse events (AEs)
Time frame: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
- UT MD Anderson Cancer CenterLink provided by the sponsor.
Related trials for Data Collection
Enrolling by invitationObservational study
Data Collection, Clinical Care and Interventions in CCR, NCI
Neoplasms, Cancer
Not yet recruitingObservational study
Integration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.
Resectable Hepatocellular Carcinoma (HCC)
RecruitingObservational study
Natural History Study of Kaposi Sarcoma
Kaposi Sarcoma, HIV
RecruitingObservational study
The Indiana Myeloma Registry
Plasma Cell Dyscrasias
RecruitingObservational study
Collection of Clinical Data and Specimens for Research in Hearing, Balance, Taste, Smell, Voice, Speech, and Language Disorders.
Hearing Loss, Deafness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Partow Kebriaei, MD principal investigator
UT MD Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Data Collection and Sickle Cell Disease, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Partow Kebriaei, MD (713-745-0663, pkebriae@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
safety and adverse events (AEs) (time frame: Through study completion; an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.